What is the recommended acute management pathway for a patient with an acute on chronic heart failure exacerbation?

Acute Management Pathway for Acute-on-Chronic Heart Failure Exacerbation

Immediate intravenous diuretics are the cornerstone of acute decompensated heart failure management, with initial dosing of 20-40 mg IV furosemide for diuretic-naive patients or at least equivalent to the oral dose for those on chronic therapy, combined with continuous monitoring of symptoms, urine output, renal function, and electrolytes. 1

Initial Assessment and Diagnosis

Immediate Diagnostic Workup

• Measure plasma natriuretic peptides (BNP, NT-proBNP, or MR-proANP) upon presentation in all patients with acute dyspnea to differentiate acute heart failure from non-cardiac causes 1
• Obtain immediate ECG and echocardiography to assess cardiac function and identify precipitating factors 1
• Monitor oxygen saturation with pulse oximetry (SpO2) and obtain acid-base balance, especially in patients with acute pulmonary edema or COPD history 1

Clinical Phenotyping

Assess the patient's hemodynamic profile based on:

• Congestion status: orthopnea, paroxysmal nocturnal dyspnea, breathlessness, bi-basilar rales, jugular venous distension, peripheral edema 1
• Perfusion status: systolic blood pressure, signs of hypoperfusion (oliguria, cold peripheries, altered mental status) 1

Pharmacological Management Algorithm

Diuretic Therapy (First-Line)

Dosing strategy: 1

• New-onset heart failure or no maintenance diuretics: 20-40 mg IV furosemide initially
• Chronic oral diuretic therapy: IV bolus at least equivalent to oral dose
• Administration: Either intermittent boluses or continuous infusion, adjusted according to symptoms and clinical status
• Monitoring: Regular assessment of symptoms, urine output, renal function, and electrolytes is mandatory

Refractory cases: 1

• Consider combination therapy with thiazide-type diuretic or spironolactone for inadequate response

Vasodilator Therapy (Adjunctive)

IV vasodilators should be considered for symptomatic relief when systolic BP >90 mmHg 1

• Hypertensive acute heart failure (SBP >110 mmHg): Consider IV vasodilators as initial therapy to improve symptoms and reduce congestion
• Alternative: Sublingual nitrates may be considered 1
• Critical monitoring: Symptoms and blood pressure must be monitored frequently during administration

Respiratory Support

Non-invasive positive pressure ventilation (CPAP or bi-level PPV) should be started as soon as possible in patients with respiratory distress 1

• Oxygen therapy: Consider when SpO2 <90%, but avoid hyperoxia 1
• CPAP: Feasible in pre-hospital setting, simpler technique requiring minimal training 1
• PS-PEEP preferred: For patients with acidosis and hypercapnia, particularly with COPD history or signs of fatigue 1
• Benefits: Reduces respiratory distress, may decrease intubation and mortality rates 1

Inotropic Support (Restricted Use)

Inotropic agents are NOT recommended unless the patient is symptomatically hypotensive (SBP <90 mmHg) or hypoperfused due to safety concerns 1

When indicated (hypotension with hypoperfusion): 1

• Short-term IV infusion of dobutamine, dopamine, levosimendan, or PDE III inhibitors may be considered
• Levosimendan or PDE III inhibitor may be considered to reverse beta-blockade effects if contributing to hypotension
• Vasopressors (norepinephrine preferably): May be considered in cardiogenic shock despite other inotrope treatment 1

Critical Management Considerations

Continue Guideline-Directed Medical Therapy

Every attempt should be made to continue evidence-based, disease-modifying therapies in the absence of hemodynamic instability or contraindications 1

• Do not routinely discontinue ACE inhibitors, ARBs, beta-blockers, or mineralocorticoid receptor antagonists unless specifically contraindicated

Cardiogenic Shock Protocol

All patients with cardiogenic shock should be rapidly transferred to a tertiary care center with 24/7 cardiac catheterization and dedicated ICU/CCU with availability of short-term mechanical circulatory support 1

Cardiogenic shock definition: 1

• Hypotension (SBP <90 mmHg) despite adequate filling status
• Signs of hypoperfusion: oliguria, cold peripheries, altered mental status, lactate >2 mmol/L, metabolic acidosis, SvO2 <65%

Triage and Disposition Criteria

ICU/CCU admission criteria: 1

• Respiratory rate >25
• SaO2 <90%
• Use of accessory muscles for breathing
• Systolic BP <90 mmHg
• Need for intubation
• Signs of hypoperfusion (oliguria, cold peripheries, altered mental status, lactate >2 mmol/L, metabolic acidosis, SvO2 <65%)

Cardiology ward admission strongly recommended as hospitalization in a cardiology department is associated with reduced in-hospital mortality 2

Monitoring During Hospitalization

Daily monitoring requirements: 1

• Daily weight and accurate fluid balance chart
• Standard non-invasive monitoring: pulse, respiratory rate, blood pressure
• Daily renal function and electrolytes
• Pre-discharge natriuretic peptide measurement for post-discharge planning

Common Pitfalls to Avoid

Medications to Avoid

The following medications are contraindicated or not recommended: 1

• Thiazolidinediones (glitazones): Increase risk of heart failure worsening and hospitalization
• NSAIDs or COX-2 inhibitors: Increase risk of heart failure worsening and hospitalization
• Adaptive servo-ventilation: Not recommended in HFrEF with predominant central sleep apnea due to increased mortality

Sedation Considerations

Midazolam is preferred over propofol in patients with acute heart failure or cardiogenic shock, as propofol can induce hypotension and have cardiodepressive side effects 1

Avoid Iatrogenic Complications

Minimize unnecessary urinary catheterization and prolonged emergency department boarding, especially in frail patients 3